Amelie G. Ramirez, DrPH, MPH, director of the Institute for Health Promotion Research at UT Health Science Center San Antonio, discussed the need for standardized questionnaires for clinicians to discuss social determinants of health with their oncology patients.
The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.
Amanda Hickman, PharmD, MPH, MSCS, discusses the clinical assessment to lower migraines (CALM) in an HSSP setting.
Experts discuss the critical role of specialty pharmacists in advocating for patients during challenging moments in their hemophilia treatment journey and explore precision dosing considerations and the importance of adherence to dosing guidelines.
Atta Chowdhry, RPh, and Lisa Schrade, PharmD, discuss best practices in coordinating specialty pharmacy services between payers and prescribers to ensure timely access to critical hemophilia treatments.
Mridula George discusses the role of personalized circulating tumor DNA monitoring in predicting the response to neoadjuvant therapy for early-stage breast cancer.
Peter J. Siavelis, discusses the role of the InteLogix platform to enable a more rapid response to changes in the pharmaceutical supply chain.
Jennifer N. Clements PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP discusses the role of Semaglutide and Tirzepatide for type 2 diabetes and obesity
Marlo Blazer, PharmD, BCOP, discusses the collaborative nature of the pharmacist's role within the oncology care team.
Lisa Schrade, PharmD, and Robert Sidonio Jr, MD, MSc, explore the integral partnership between specialty pharmacists and hematologists in managing patients with hemophilia.
Atta Chowdhry, RPh, and Robert Sidonio Jr, MD, MSc, discuss the safety and efficacy of gene therapy for hemophilia A, highlighting recent approvals, with insights into adverse effects, immunosuppression, and the evolving treatment landscape.
Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses the multifaceted involvement of oncology pharmacists in various aspects of patient care.
Lisa Schrade, PharmD, and Robert Sidonio Jr, MD, MSc, discuss real-world evidence for hemophilia A therapies, highlighting their safety, efficacy, and impact on bleeding events, nurse visits, and hospital visits.
Experts discuss adherence to emicizumab in real-world settings, comparing it to factor products and highlighting the convenience and ease of administration associated with emicizumab.
Denise Giambalvo, director of Member Engagement & Business Strategy at the Washington Health Alliance and recently led a biosimilars initiative for the coalition, discusses biosimilar influence of pricing for biologic drugs, trends to expect in 2024, and why education on biosimilars are important for patients, pharmacists, prescribers, and more
Pharmacists address aspects of patient care that are unique to the focus of the pharmacist, such as financial toxicity and data collection for components of social determinants of health (SDOH).
Cheryl Larson, president and CEO of the Midwest Business Group on Health, discussed the employers’ perspectives on pharmacy benefit manager (PBM) reform efforts and how they can dovetail with the concerns of pharmacies.
Christian John Lillis, co-founder and executive director at Peggy Lillis Foundation, discusses the role of the pharmacist in education that advances C diff awareness in the medical community.
In the second part of his interview with Pharmacy Times, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed pharmacists’ role in HIV education and management.
With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.
Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.
Lisa Deschamps, CEO of AviadoBio, discusses frontotemporal dementia and AVB-101, a one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene and restoring progranulin levels in the brain.
Expert discusses changes health care professionals should know about drug coverage and out-of-pocket costs through the IRA
Robert Sidonio Jr, MD, MSc, discusses studies on inhibitor formation in patients with hemophilia A using prophylaxis, addressing the challenges of mitigating inhibitor risk and the impact on treatment strategies.
Lisa Schrade, PharmD, explores the implications of real-world data comparing standard half-life and extended half-life products in hemophilia A treatment.
Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.
Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.
Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.
Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.
Experts discuss challenges and recommendations for addressing diversity, equity, and inclusion in pharmacy programs for minority students.
